These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 34826968)
1. After the Storm: Ophthalmic Manifestations of COVID-19 Vaccines. Sen M; Honavar SG Indian J Ophthalmol; 2021 Dec; 69(12):3398-3420. PubMed ID: 34826968 [TBL] [Abstract][Full Text] [Related]
2. Uveitis and Posterior Ophthalmic Manifestations Following the SARS-CoV-2 (COVID-19) Vaccine. Patel KG; Hilton T; Choi RY; Abbey AM Ocul Immunol Inflamm; 2022 Jul; 30(5):1142-1148. PubMed ID: 35763603 [TBL] [Abstract][Full Text] [Related]
3. Ocular adverse effects of COVID-19 vaccines: A systematic review. Kumari S; Anand R; Sambyal B; Singh Y; Rangappa P; Jha SK J Family Med Prim Care; 2022 Sep; 11(9):5041-5054. PubMed ID: 36505575 [TBL] [Abstract][Full Text] [Related]
4. COVID-19 and Eye: A Review of Ophthalmic Manifestations of COVID-19. Sen M; Honavar SG; Sharma N; Sachdev MS Indian J Ophthalmol; 2021 Mar; 69(3):488-509. PubMed ID: 33595463 [TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
6. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data. Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939 [TBL] [Abstract][Full Text] [Related]
7. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336 [TBL] [Abstract][Full Text] [Related]
8. COVID-19 and cardiovascular disease: manifestations, pathophysiology, vaccination, and long-term implication. Abdel Moneim A; Radwan MA; Yousef AI Curr Med Res Opin; 2022 Jul; 38(7):1071-1079. PubMed ID: 35575011 [TBL] [Abstract][Full Text] [Related]
9. Ocular Manifestations after Receiving COVID-19 Vaccine: A Systematic Review. Lee YK; Huang YH Vaccines (Basel); 2021 Nov; 9(12):. PubMed ID: 34960150 [TBL] [Abstract][Full Text] [Related]
10. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease. Beckley M; Olson AK; Portman MA JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521 [TBL] [Abstract][Full Text] [Related]
11. An overview on inactivated and live-attenuated SARS-CoV-2 vaccines. Khoshnood S; Arshadi M; Akrami S; Koupaei M; Ghahramanpour H; Shariati A; Sadeghifard N; Heidary M J Clin Lab Anal; 2022 May; 36(5):e24418. PubMed ID: 35421266 [TBL] [Abstract][Full Text] [Related]
12. SARS-COV-2 Infection, Vaccination, and Immune-Mediated Diseases: Results of a Single-Center Retrospective Study. Luchetti Gentiloni MM; Paci V; Marconi V; Gigli M; Benfaremo D; Sordillo R; Macchini C; Massaccesi L; Perna GP; Offidani AM; Moroncini G Front Immunol; 2022; 13():859550. PubMed ID: 35386714 [TBL] [Abstract][Full Text] [Related]
13. Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint. Chen X; Wang W; Chen X; Wu Q; Sun R; Ge S; Zheng N; Lu W; Yang J; Rodewald L; Yu H BMC Med; 2022 Jan; 20(1):36. PubMed ID: 35086547 [TBL] [Abstract][Full Text] [Related]
14. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Chia PY; Ong SWX; Chiew CJ; Ang LW; Chavatte JM; Mak TM; Cui L; Kalimuddin S; Chia WN; Tan CW; Chai LYA; Tan SY; Zheng S; Lin RTP; Wang L; Leo YS; Lee VJ; Lye DC; Young BE Clin Microbiol Infect; 2022 Apr; 28(4):612.e1-612.e7. PubMed ID: 34826623 [TBL] [Abstract][Full Text] [Related]
15. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359 [TBL] [Abstract][Full Text] [Related]
19. Ocular Inflammatory Reactions following an Inactivated SARS-CoV-2 Vaccine: A Four Case Series. Ren J; Zhang T; Li X; Liu G Ocul Immunol Inflamm; 2023 Aug; 31(6):1128-1133. PubMed ID: 35819841 [TBL] [Abstract][Full Text] [Related]
20. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis. Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]